Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2551
CALL
Vertiv
VRT
$111B
| $3.24M | ﹤0.01% |
+20,000
| New | +$3.47M |
|
2552
Bank of N.T. Butterfield & Son
NTB
$2.5B
| $3.24M | ﹤0.01% |
64,984
+5,886
| +10% | +$271K |
|
|
GOOS
2553
PUT
Canada Goose Holdings
GOOS
$850M
| $3.24M | ﹤0.01% |
250,000
| – | – |
|
2554
iShares TIPS Bond ETF
TIP
$14.7B
| $3.23M | ﹤0.01% |
29,404
-1,110
| -4% | -$123K |
|
|
CCRN
2555
DELISTED
Cross Country Healthcare
CCRN
| $3.23M | ﹤0.01% |
398,851
+354,771
| +805% | +$3.88M |
|
2556
Rigel Pharmaceuticals
RIGL
$762M
| $3.23M | ﹤0.01% |
75,359
+24,294
| +48% | +$916K |
|
2557
PUT
Tradeweb Markets
TW
$21.9B
| $3.23M | ﹤0.01% |
+30,000
| New | +$3.22M |
|
|
AVDL
2558
DELISTED
Avadel Pharmaceuticals
AVDL
| $3.21M | ﹤0.01% |
148,858
-1,515
| -1% | -$29.4K |
|
2559
Marriott Vacations Worldwide
VAC
$4.17B
| $3.21M | ﹤0.01% |
55,596
-49,452
| -47% | -$2.92M |
|
2560
CALL
Enphase Energy
ENPH
$5.39B
| $3.21M | ﹤0.01% |
100,000
| – | – |
|
2561
WisdomTree
WT
$3.44B
| $3.2M | ﹤0.01% |
262,697
+71,048
| +37% | +$858K |
|
2562
OceanFirst Financial
OCFC
$1.85B
| $3.2M | ﹤0.01% |
178,397
+26,276
| +17% | +$491K |
|
2563
Western Union
WU
$2.34B
| $3.2M | ﹤0.01% |
343,643
-133,539
| -28% | -$1.18M |
|
2564
Pathward Financial
CASH
$1.78B
| $3.2M | ﹤0.01% |
45,019
+8,368
| +23% | +$600K |
|
|
WSR
2565
DELISTED
Whitestone REIT
WSR
| $3.2M | ﹤0.01% |
230,104
+2,864
| +1% | +$36.9K |
|
2566
World Kinect Corp
WKC
$1.89B
| $3.19M | ﹤0.01% |
136,339
+20,534
| +18% | +$506K |
|
2567
Compass Therapeutics
CMPX
$407M
| $3.19M | ﹤0.01% |
594,776
+372,358
| +167% | +$1.72M |
|
|
ONC
2568
CALL
BeOne Medicines Ltd
ONC
$40.6B
| $3.19M | ﹤0.01% |
10,500
-3,000
| -22% | -$982K |
|
|
ONC
2569
PUT
BeOne Medicines Ltd
ONC
$40.6B
| $3.19M | ﹤0.01% |
10,500
-3,000
| -22% | -$982K |
|
2570
QuidelOrtho
QDEL
$1.03B
| $3.17M | ﹤0.01% |
111,027
+4,949
| +5% | +$134K |
|
2571
1st Source
SRCE
$2.13B
| $3.16M | ﹤0.01% |
50,498
+9,097
| +22% | +$563K |
|
2572
CALL
Option Care Health
OPCH
$3.57B
| $3.15M | ﹤0.01% |
+99,000
| New | +$2.91M |
|
2573
PUT
Synchrony
SYF
$26.1B
| $3.15M | ﹤0.01% |
37,800
+17,800
| +89% | +$1.36M |
|
2574
Invesco Senior Loan ETF
BKLN
$6.76B
| $3.15M | ﹤0.01% |
+150,000
| New | +$3.14M |
|
2575
CoreCivic
CXW
$3.32B
| $3.15M | ﹤0.01% |
164,787
+10,691
| +7% | +$196K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.